Indefinite Delivery Contract SPE2DR25D9949

The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of a comprehensive range of pharmaceutical products and medical supplies. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide.

This IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which seeks to establish multiple regional contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, the U.S. Coast Guard, and the U.S. Naval Fleet. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. Awards will be made on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally.